← Back to Search

Opioid Analgesic

Pain Medication for Postoperative Pain

Phase 3
Recruiting
Led By David Greenberg, MD
Research Sponsored by St. Louis University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Femoral Shaft or Neck bone lesion
18 years old or greater
Must not have
History of Peptic Ulcer Disease
History of heart failure or cardiovascular disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to six weeks post-op
Awards & highlights

Summary

This trial is testing whether adding Toradol, an anti-inflammatory drug, to the usual opioid painkillers can better manage pain after surgery in patients who have had a specific type of bone surgery. These patients are chosen because they don't need the body's natural inflammation process for healing. Toradol works by reducing inflammation, while opioids change how the brain perceives pain. Toradol, also known as ketorolac, is a nonsteroidal anti-inflammatory drug (NSAID) that has been studied for its opioid-sparing effects in postoperative pain management.

Who is the study for?
This trial is for adults planning to undergo prophylactic intramedullary nailing of the femur due to bone lesions. It's not suitable for those with coagulation disorders, current fractures, severe kidney or liver disease, peptic ulcer disease, certain heart conditions, allergies to acetaminophen or NSAIDs, opioid addiction or dependence, pregnancy, and those on specific medications like probenecid.
What is being tested?
The study investigates the effectiveness of using a pain reliever called Toradol in combination with opioids versus just opioids alone after surgery for securing weak bones in patients without fractures. The goal is to see if adding an NSAID can help manage post-op pain without affecting healing.
What are the potential side effects?
Possible side effects include risk of bleeding from Toradol (an NSAID), stomach ulcers, kidney problems; and from opioids: drowsiness, constipation, nausea/vomiting and potential dependency issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a bone lesion in my femur.
Select...
I am 18 years old or older.
Select...
I am planning to have surgery to prevent fractures in my thigh bone.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had peptic ulcer disease in the past.
Select...
I have a history of heart failure or heart disease.
Select...
I have had heart bypass surgery.
Select...
I am on chemotherapy that doesn't allow for NSAID use.
Select...
I have a fracture caused by my cancer.
Select...
I cannot use toradol due to my liver condition.
Select...
I am currently taking the medication probenecid.
Select...
I have had severe kidney problems in the past.
Select...
I have a blood clotting disorder or need blood-thinning medication during the study.
Select...
I am currently taking Pentoxifylline.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to six weeks post-op
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to six weeks post-op for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Milligram Morphine Equivalent (MME) of Opioid Medications Utilized
Secondary study objectives
Numerical Rating Scale (NRS)
Patient Reported Outcomes Measurement System (PROMIS) Pain Intensity Scale
Single Assessment Numerical Evaluation (SANE)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental ArmExperimental Treatment6 Interventions
For the first 24 hours following surgery, patients younger than 65 years old will be administered a maximum of 120 mg/day bolus IV ketorolac (30 mg every 6 hours). Patients older than 65 years old or with history of advanced renal impairment will receive a maximum of 60 mg/day bolus IV ketorolac (15 mg every 6 hours). All patients may also be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate- severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. At discharge, they will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours, quantity 50. Those with preexisting liver disease will be prescribed the equivalent in oxycodone and will not receive acetaminophen for mild pain.
Group II: ControlPlacebo Group6 Interventions
Following surgery, patients will be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate-severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. They will also be given a placebo injection of normal saline every 6 hours for the first 24 hours following surgery. At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours PRN quantity 50, unless they have preexisting liver disease, in which case they will be prescribed the equivalent in oxycodone. They will not receive a nerve block.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oxycodone Acetaminophen
2017
Completed Phase 3
~180
Hydrocodone/Acetaminophen
2020
Completed Phase 4
~300
Ketorolac
2014
Completed Phase 4
~1760
Morphine
2013
Completed Phase 4
~2230
Acetaminophen
2017
Completed Phase 4
~2030
Oxycodone
2014
Completed Phase 4
~2210

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Nonsteroidal anti-inflammatory drugs (NSAIDs) like Toradol (ketorolac) work by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes are crucial in the biosynthesis of prostaglandins, which are lipid compounds that mediate inflammation, pain, and fever. By blocking COX enzymes, NSAIDs reduce the production of prostaglandins, thereby alleviating pain and inflammation. This mechanism is particularly important for pain patients as it provides a non-opioid option for pain relief, potentially reducing the risk of opioid dependency and associated side effects. Understanding this mechanism helps in selecting appropriate pain management strategies tailored to individual patient needs and comorbidities.
Central Nervous System Targets: Supraspinal Mechanisms of Analgesia.Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence.The Role of Descending Modulation in Manual Therapy and Its Analgesic Implications: A Narrative Review.

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
194 Previous Clinical Trials
41,863 Total Patients Enrolled
David Greenberg, MDPrincipal Investigator - St. Louis University
St. Louis University Hospital
Georgetown University School Of Medicine (Medical School)
University Mo-Columbia School Medicine (Residency)
1 Previous Clinical Trials
38 Total Patients Enrolled

Media Library

Hydrocodone/Acetaminophen (Opioid Analgesic) Clinical Trial Eligibility Overview. Trial Name: NCT03823534 — Phase 3
Pain Research Study Groups: Experimental Arm, Control
Pain Clinical Trial 2023: Hydrocodone/Acetaminophen Highlights & Side Effects. Trial Name: NCT03823534 — Phase 3
Hydrocodone/Acetaminophen (Opioid Analgesic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03823534 — Phase 3
~9 spots leftby Sep 2025